TP53 and neoplasm: Ginsenoside compound K (22) therapy of tumor cells causes sensitizing TNFRSF10A/TRAIL/APO2L1 (TNF receptor superfamily member 10a) and TNFRSF10A-triggered apoptosis through autophagy-related and -independent (TP53-DDIT3 pathway) TNFRSF10B upregulation [173].